Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01352728 | Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | completed | Phase 2 | 50 | Chinese University of Hong KongOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT00906373 | A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver | completed | Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00101036 |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery |
| completed |
| Phase 2 |
| 57 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Apr 20, 2018 |
| clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT00321594 | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Nov 6, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02007954 | Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma(DEBDOX) | completed | Phase 2 | 24 | Yale UniversityOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01375569 | TRC105 for Liver Cancer That Has Not Responded to Sorafenib | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 28, 2017 | clinicaltrials |
| NCT02089633 | Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC(PACOX) | completed | Phase 2 | 17 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT01639352 | Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 20 | Lynn FeunOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01357486 | Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis(PRODIGE 21) | completed | Phase 2 | 160 | University Hospital, BordeauxOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | completed | Phase 2 | 566 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 16, 2017 | clinicaltrials |
| NCT01522937 | A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer | completed | Phase 2 | 94 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01507064 | Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma(LANEX) | completed | Phase 2 | 40 | Cardarelli HospitalOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01273662 | Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 45 | National Taiwan University HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03048123 | HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B | completed | Phase 2 | 79 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00273312 | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 7, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02447679 | Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence | completed | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02576964 | A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer | completed | Phase 2 | 16 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00508001 | Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 67 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT01777594 | Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma(G-202-003) | completed | Phase 2 | 25 | GenSpera, Inc.INDUSTRY | 1 | Aug 23, 2016 | clinicaltrials |
| NCT01911000 | Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis | completed | Phase 2 | 69 | Samsung Medical CenterOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01559844 | Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | completed | Phase 2 | 61 | Gilead SciencesINDUSTRY | 3 | Jul 27, 2016 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01964001 | The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer | completed | Phase 2 / Phase 3 | 71 | Taichung Veterans General HospitalOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT01374750 | Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)(Sirolimus) | completed | Phase 2 | 45 | Seoul National University HospitalOTHER | 1 | Jun 1, 2016 | clinicaltrials |
| NCT02745483 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies: Follow-up Study | completed | Phase 2 | 153 | Seoul National University HospitalOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01488487 | Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 7, 2016 | clinicaltrials |
| NCT02683538 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies | completed | Phase 2 | 196 | Seoul National University HospitalOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00872014 | A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer | completed | Phase 2 | 60 | AmgenINDUSTRY | 0 | Apr 4, 2016 | clinicaltrials |
| NCT00814242 | Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels | completed | Phase 2 / Phase 3 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00819650 | A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection | completed | Phase 2 | 200 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00820053 | A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection | completed | Phase 2 | 450 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00820339 | Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy(SHVE) | completed | Phase 2 / Phase 3 | 132 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00827554 | The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00849264 | Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients | completed | Phase 2 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed(HCC) | completed | Phase 2 | 2 | University of PittsburghOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00987935 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | completed | Phase 2 | 134 | Boehringer IngelheimINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00055692 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00807300 | Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma(CEAL) | completed | Phase 2 | 77 | University of MagdeburgOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02008929 | to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)(MG4101) | completed | Phase 2 | 5 | Samsung Medical CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00524498 | A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00365391 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jun 20, 2018source: clinicaltrials